Modified bismuth-containing eradication treatment — Competitive Intelligence Brief

Modified bismuth-containing eradication treatment (Modified bismuth-containing eradication treatment) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimicrobial combination therapy. Area: Gastroenterology / Infectious Disease.

marketed Antimicrobial combination therapy Helicobacter pylori cell wall and urease enzyme Gastroenterology / Infectious Disease Small molecule

Target snapshot

Modified bismuth-containing eradication treatment (Modified bismuth-containing eradication treatment) — Athens Medical Center. Bismuth-containing compounds eradicate Helicobacter pylori by disrupting bacterial cell wall integrity and inhibiting urease enzyme activity.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Modified bismuth-containing eradication treatment TARGET	Modified bismuth-containing eradication treatment	Athens Medical Center	marketed	Antimicrobial combination therapy	Helicobacter pylori cell wall and urease enzyme
Bismuth-based susceptibility-guided treatment	Bismuth-based susceptibility-guided treatment	National Cheng-Kung University Hospital	marketed	Antimicrobial combination therapy (bismuth-based)	Helicobacter pylori cell wall and bacterial proteins
standard quadruple therapy	standard quadruple therapy	Les Laboratoires des Médicaments Stériles	marketed	Antimicrobial combination therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimicrobial combination therapy class)

1. Athens Medical Center · 1 drug in this class
2. Les Laboratoires des Médicaments Stériles · 1 drug in this class